

CORRECTION

Correction: Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: A prospective, non-randomized pilot study


Garrick D. Talmage, Oscar J. M. Coppes, Adil Javed, Jacqueline Bernard

There are errors in the author affiliations. The affiliations should appear as shown here: Garrick D. Talmage¹, Oscar J. M. Coppes², Adil Javed³, Jacqueline Bernard⁴

1 Department of Otolaryngology, University of Colorado, Aurora, Colorado, United States of America, **2** Department of Anesthesia, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States of America, **3** Department of Neurology, The University of Chicago, Chicago, Illinois, United States of America, **4** Department of Neurology, Oregon Health Science University, Portland, Oregon, United States of America.

Reference

1. Talmage GD, Coppes OJM, Javed A, Bernard J (2017) Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: A prospective, non-randomized pilot study. PLoS ONE 12(4): e0173299. <https://doi.org/10.1371/journal.pone.0173299> PMID: 28426702



OPEN ACCESS

Citation: Talmage GD, Coppes OJM, Javed A, Bernard J (2017) Correction: Natalizumab stabilizes physical, cognitive, MRI, and OCT markers of disease activity: A prospective, non-randomized pilot study. PLoS ONE 12(5): e0178338. <https://doi.org/10.1371/journal.pone.0178338>

Published: May 18, 2017

Copyright: © 2017 Talmage et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.